Filter
779
Text search:
in
vitro
Featured
Recommendations
94
New Publications
142
Language
Document type
No document type
323
Guidelines
220
Studies & Reports
113
Manuals
63
Strategic & Response Plan
22
Fact sheets
21
Training Material
9
Situation Updates
4
Resource Platforms
3
Brochures
1
Countries / Regions
India
30
Latin America and the Carribbean
24
Russia
23
Germany
22
South Africa
20
Brazil
16
Global
15
Africa
13
Colombia
11
Western and Central Europe
11
Argentina
9
Peru
9
Kenya
8
Bolivia
8
Ethiopia
7
Zambia
7
Paraguay
7
Eastern Europe
7
Namibia
6
Ukraine
6
Venezuela
6
Uganda
5
Tanzania
5
Rwanda
5
El Salvador
5
Burkina Faso
4
Nigeria
4
Cameroon
4
Indonesia
4
West and Central Africa
4
Middle East and North Africa
4
Sierra Leone
3
Congo, Democratic Republic of
3
Mali
3
Niger
3
Nepal
3
Benin
3
Eswatini/ Swaziland
3
Ecuador
3
Lesotho
3
Myanmar / Burma
3
East and Southern Africa
3
Eastern Europe and Central Asia
3
Congo-Brazzaville
3
France
3
Spain
3
Guinea
2
Liberia
2
Senegal
2
Côte d’Ivoire / Ivory Coast
2
Haiti
2
Philippines
2
Syria
2
Chad
2
Bangladesh
2
Malawi
2
Angola
2
Madagascar
2
Chile
2
Yemen
2
Asia
2
Tajikistan
2
Kazakhstan
2
Guinea-Bissau
1
Morocco
1
USA
1
Saudi Arabia
1
Ghana
1
Togo
1
Zimbabwe
1
Somalia
1
South Sudan
1
Iraq
1
Jordan
1
Lebanon
1
Turkey
1
Egypt
1
Gambia
1
Mauritania
1
Mozambique
1
Sudan
1
Dominican Republic
1
North Macedonia
1
Serbia
1
Cuba
1
Burundi
1
Honduras
1
Libya
1
Guatemala
1
Mexico
1
Nicaragua
1
South–East Asia Region
1
Luxembourg
1
Albania
1
Djibouti
1
Armenia
1
Mongolia
1
Southern Africa
1
Laos
1
Canada
1
Qatar
1
Uzbekistan
1
Kyrgyzstan
1
Georgia
1
North America
1
Belgium
1
Tunisia
1
Belarus
1
Israel
1
Authors & Publishers
Publication Years
Category
Countries
228
Clinical Guidelines
147
Pharmacy & Technologies
42
Women & Child Health
22
Public Health
20
Key Resources
16
Toolboxes
COVID-19
141
TB
107
HIV
85
AMR
49
NTDs
42
Pharmacy
31
Ebola
28
Rapid Response
26
Zika
16
Caregiver
14
Refugee
13
Planetary Health
12
Mental Health
11
Polio
6
NCDs
5
Conflict
3
Specific Hazards
3
Global Health Education
3
Cholera
2
Natural Hazards
2
Disability
1
Social Ethics
1
Journal of Infectious Diseases and Therapeutics, 2013, 1, 17-24
Mem Inst Oswaldo Cruz , Rio de Janeiro, Vol. 110 (3): 377-386, May 2015
This volume introduces Mongolian traditional medicine and details the nature and uses of medicinal plants found in the country.
The book focuses on the medicinal plants used most commonly in Mongol
...
Buruli ulcer (BU) is a bacterial skin infection that is caused by Mycobacterium ulcerans and mainly affects people who reside in the rural areas of Africa and in suburban and beach resort communitie
...
This guideline provides advice in regards to applications for Marketing Authorisations for antimicrobial veterinary medicinal products (VMPs) on the data required and the methodology to be used for performing an assessment of the risk to public heal
...
PQDx 0181-031-00
WHO PQ Public Report
March/2017, version 3.0
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive
...
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
TECHNICAL SPECIFICATIONS FOR TEST SELECTION ESSENTIAL IN VITRO DIAGNOSTIC TESTS FOR SARS-COV-2
Nat Commun 9, 5370 (2018). https://doi.org/10.1038/s41467-018-07804-8. Mycobacterium ulcerans is the causative agent of Buruli ulcer, a neglected tropical skin disease that is most commonly found in children from West and Central Africa. Despite the
...
These guidelines have been developed for scientific purpose with the main aim to guide the regulatory authority for evaluating probiotic products in our country.
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
Technical specifications for selection of essential in vitro diagnostic tests for SARS-COV-2, 14 June 2021
Afr J Tradit Complement Altern Med. (2016) 13(4):123-131
Out of 400 questionnaires distributed to the participants, 389 were returned with data acceptable for analysis. Ages of the participants ranged from 18 to 75 years (Mean=43 + 11.6). Out of the 272 (69.9%) participants who conceded that th ...
Out of 400 questionnaires distributed to the participants, 389 were returned with data acceptable for analysis. Ages of the participants ranged from 18 to 75 years (Mean=43 + 11.6). Out of the 272 (69.9%) participants who conceded that th ...
Value in Health Regional Issues 4 C (2014) 37-40
PQDx 0018-010-00 WHO
PQDx PR
July/2016, version 3.0
Communication to Healthcare Professionals Mar-2020
This guideline is intended to assist healthcare professionals in the participation of very important process of continuous surveillance of safety and efficacy of the health products which are used
...
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. Th
...
